Published in Vaccine Weekly, November 25th, 2009
today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million. Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one of its top three markets worldwide. The comments were made by Novartis' CEO, Daniel Vasella, in an interview with The Wall Street Journal. http://www.chinabiotoday.com/articles/20091103_1
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly